CRBP Company Profile and Key Details

Q: Who are the executives of CRBP?

Ms. Christina BertschHead of HRDr. Rachael Brake Ph.D.Chief Scientific OfficerScott ConstantineSenior Director & Head of Clinical OperationsDr. Yuval Cohen Ph.D.Chief Executive Officer & DirectorMs. Lindsey SmithHead of Corporation Communications & Patient AdvocacyMr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial OfficerTed JenkinsVice President & Head of Investor Relations

NASDAQ : CRBP

Corbus Pharmaceuticals

$10.52

0.22+2.14%

At Close 4:00 PM

59.98

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock surged +2.14%, trading at $10.52 on NASDAQ, up from the previous close of $10.30. The stock opened at $10.29, fluctuating between $10.03 and $10.70 in the recent session.

Stock Snapshot

10.3

Prev. Close

131.87M

Market Cap

10.025

Day Low

-1.74

P/E Ratio

-6.06

EPS (TTM)

-8.16

Cash Flow per Share

10.29

Open

12.54M

Number of Shares

10.7

Day High

87.41%

Free Float in %

-1.56

Book Value

274.94K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	10.29	10.70	10.03	10.52	282.21K
Apr 30, 2026	9.85	10.17	9.57	9.88	331.87K
Apr 29, 2026	10.29	10.50	9.61	9.82	363.82K
Apr 28, 2026	10.04	10.29	9.70	9.82	208.07K
Apr 27, 2026	10.06	10.79	9.92	10.08	458.04K
Apr 23, 2026	10.48	10.62	9.95	10.22	260.32K
Apr 22, 2026	10.45	10.81	10.23	10.48	319.63K
Apr 21, 2026	10.73	10.75	10.13	10.30	185.57K
Apr 20, 2026	10.57	10.97	10.44	10.62	318.63K
Apr 17, 2026	10.25	11.00	10.15	10.59	546.08K
Apr 16, 2026	9.97	10.27	9.93	10.14	174.53K
Apr 14, 2026	10.15	10.65	10.00	10.02	272.8K
Apr 13, 2026	9.80	10.47	9.70	10.18	127.75K
Apr 10, 2026	10.19	10.31	9.56	9.80	225.15K
Apr 09, 2026	9.82	10.73	9.81	10.32	199.83K
Apr 08, 2026	10.15	10.31	9.50	9.84	203.29K
Apr 07, 2026	9.92	10.38	9.69	9.71	251.62K
Apr 06, 2026	10.36	10.67	9.97	10.14	268.11K
Apr 02, 2026	9.98	10.50	9.89	10.17	235.86K
Apr 01, 2026	9.46	10.33	9.46	9.98	201.61K

Contact Details

Norwood, MA 02062

United States

https://www.corbuspharma.com 617 963 0100

About Company

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor � (TGF�); and CRB-602, an anti-av�6/av�8 mAb that blocks the activation of TGF� for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed at $10.52 USD, gaining $0.22 (2.14%) from the previous close of $10.30. The stock is currently mid-range between its 52-week high and low $6.10 and $20.56. With a market capitalization of about $131.87 million, Corbus Pharmaceuticals Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.68). Key stats such as the average daily volume over the past year has been around 231.29 thousand shares, in line with its 52-week average. Headquartered in Norwood, MA, Corbus Pharmaceuticals Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yuval Cohen, the company employs approximately 28 people and listed since October 27, 2014. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.

Technical Performance

CRBP has shown mixed momentum, gaining 7.51% over the past week and -55.54% over the past quarter, though year-to-date performance is up 5.53%. Short-term trend indicators are bullishly aligned (SMA20 5.46%, SMA50 0.97%, SMA200 -16.59%). The stock’s 14-day RSI is 54.22 (neutral), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.87% below its high and over 77.8% above its low. Average 10-day trading volume of 328.80 thousand shares is slightly above the 3-month average of 223.47 thousand, indicating heightened recent market interest.

Valuation Metrics

Corbus Pharmaceuticals Holdings, Inc. trades at a P/E ratio of -1.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.95 suggesting the stock is closer to book value. The P/FCF stands at -2.06, also below market averages.

Dividend & Fair Value

Corbus Pharmaceuticals Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.02. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Corbus Pharmaceuticals Holdings, Inc. generated EPS of -$5.51 over the past year. Five-year average earnings growth is 35.71%. Wall Street analysts project EPS growth of -12.92% annually over the next five years. The latest quarter delivered EPS of -$1.25. The next quarter is forecast at -$1.52. Next year's EPS is expected at $40.09. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $57.00 to $38.00. The high target offers 441.83% upside. The low target suggests 261.22% downside. The mean target is $46.57. This offers 342.68% upside. Corbus Pharmaceuticals Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended March 09, 2026, missed forecasts by -29.78%. The prior quarter beat by 5.37%. Over the last six quarters, Apple has recorded several small beats. These include 16.16% in November 07, 2024.

Shareholding & Insider Activity

Corbus Pharmaceuticals Holdings, Inc. has 12.26 million shares outstanding. The public float is 7.54 million shares, elevated short interest at 11.80% of float. This equals 1.16 million shares. The short ratio is 11.56 days. Institutional investors hold 82.49% of the float. Insiders own 0.7%. Cormorant Asset Management, LP holds 2.34 million shares, White Barbara has 206.22 thousand shares and Cohen Yuval has 174.32 thousand shares. Over the past six months, insider transactions show net selling. They sold 61.24 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Corbus Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -157.76% and ROE at 645.98%.
On valuation metrics, Corbus Pharmaceuticals trades at a P/E of -1.79, P/S of 0.00 and P/B of 0.95. The current ratio is 8.07 and quick ratio is 8.07. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -51.20 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -39.49.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Corbus Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $641.00K (margin 0.00%). Operating income was - $45.08M (margin 0.0%). Net income was- $44.60M (EPS - $10.31).
The company ended the quarter with $21.10M in cash and short-term investments, a total debt of $20.88M, and net debt of $6.97M. Total assets were $28.27M, with equity of - $6.90M. Financials further reflected weakness, with operating cash flow of - $36.10M, free cash flow of - $36.10M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Corbus Pharmaceuticals Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.85%, with price expected at $10.82 by May 18, 2026, within a range of $10.09 to $11.56 3-Month Outlook: Projected fall of -34.7%, reaching $6.87 by July 31, 2026, with a range of $4.19 to $7.28. 1-Year Outlook: Projected loss of -55.42%, with price at $4.69 by May 04, 2027, within a range of $0.00 to $0.96.

Key Takeaways

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares are flat 5.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Corbus Pharmaceuticals Holdings, Inc. trading at a premium to the broader market with a P/E of -1.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $44.23, suggesting 320.44% upside. Our AI forecast model points to short-term strength (2.85% over two weeks), a medium-term fall (-34.7% over three months), and a longer-term loss (-55.42% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock price?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) stock price is $10.52 in the last trading session. During the trading session, CRBP stock reached the peak price of $10.70 while $10.03 was the lowest point it dropped to. The percentage change in CRBP stock occurred in the recent session was 2.14% while the dollar amount for the price change in CRBP stock was $0.22.

CRBP's industry and sector of operation?

The NASDAQ listed CRBP is part of Biotechnology industry that operates in the broader Healthcare sector. Corbus Pharmaceuticals Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CRBP?

Ms. Christina Bertsch
Head of HR
Dr. Rachael Brake Ph.D.
Chief Scientific Officer
Scott Constantine
Senior Director & Head of Clinical Operations
Dr. Yuval Cohen Ph.D.
Chief Executive Officer & Director
Ms. Lindsey Smith
Head of Corporation Communications & Patient Advocacy
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA
Chief Financial Officer
Ted Jenkins
Vice President & Head of Investor Relations

How CRBP did perform over past 52-week?

CRBP's closing price is 72.46% higher than its 52-week low of $6.10 where as its distance from 52-week high of $20.56 is -48.83%.

How many employees does CRBP have?

Number of CRBP employees currently stands at 28.

Link for CRBP official website?

Official Website of CRBP is: https://www.corbuspharma.com

How do I contact CRBP?

CRBP could be contacted at phone 617 963 0100 and can also be accessed through its website. CRBP operates from 500 River Ridge Drive, Norwood, MA 02062, United States.

How many shares of CRBP are traded daily?

CRBP stock volume for the day was 274.94K shares. The average number of CRBP shares traded daily for last 3 months was 231.29K.

What is the market cap of CRBP currently?

The market value of CRBP currently stands at $131.87M with its latest stock price at $10.52 and 12.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	2.79
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CRBP Company Profile and Key Details

Corbus Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways